A new drug for a rare type of lymph-node cancer developed entirely by Shenzhen Chipscreen Biosciences reflects the growing potential for China to become a major producer of new medicines thanks to local labs, scientists and interested investors, The Wall Street Journal reported, citing industry analysts and forecasts. But despite improved intellectual property protection, cumbersome rules for drug approval and government efforts to cut health-care costs — particularly spending on drugs — could weigh on domestic firms seeking big payoffs for the decade or more of work and tremendous costs involved in drug development.
Categories